BBIO BRIDGEBIO PHARMA INC revenue, earnings and financials

For the quarter ended June 30, 2026, BRIDGEBIO PHARMA INC reported revenue of $244M (up 120.4% from a year earlier), net income of −$156M and diluted EPS of −$0.78; over the last four quarters revenue was $713M and net income −$702M; for the fiscal year ended December 2025 revenue was $502M, up 126.3% on the year before.

BBIO annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $502M, gross profit n/a, operating income −$523M, net income −$733M (margin -146.0%), EPS −$3.78
• Fiscal year ended Dec 2024: revenue $222M, gross profit n/a, operating income −$593M, net income −$543M (margin -244.9%), EPS −$2.88
• Fiscal year ended Dec 2023: revenue $9.30M, gross profit n/a, operating income −$607M, net income −$653M (margin -7021.9%), EPS −$3.95
• Fiscal year ended Dec 2022: revenue $77.6M, gross profit n/a, operating income −$512M, net income −$485M (margin -624.1%), EPS −$3.26
• Fiscal year ended Dec 2021: revenue $69.7M, gross profit n/a, operating income −$577M, net income −$586M (margin -841.2%), EPS −$3.90

BBIO quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $244M (up 120.4% year over year), net income −$156M, EPS −$0.78
• Quarter ended Mar 31, 2026: revenue $195M (up 66.8% year over year), net income −$167M, EPS −$0.84
• Quarter ended Dec 31, 2025 (from the annual report): revenue $154M (up 2521.2% year over year), net income −$195M, EPS −$1.00
• Quarter ended Sep 30, 2025: revenue $121M (up 4318.0% year over year), net income −$185M, EPS −$0.95
• Quarter ended Jun 30, 2025: revenue $111M (up 4999.9% year over year), net income −$184M, EPS −$0.95
• Quarter ended Mar 31, 2025: revenue $117M (down 44.8% year over year), net income −$170M, EPS −$0.88
• Quarter ended Dec 31, 2024 (from the annual report): revenue $5.88M (up 237.1% year over year), net income −$267M, EPS −$1.43
• Quarter ended Sep 30, 2024: revenue $2.73M (down 33.2% year over year), net income −$164M, EPS −$0.86
• Quarter ended Jun 30, 2024: revenue $2.17M (up 32.1% year over year), net income −$75.5M, EPS −$0.39
• Quarter ended Mar 31, 2024: revenue $211M (up 11461.9% year over year), net income −$36.2M, EPS −$0.20
• Quarter ended Dec 31, 2023 (from the annual report): revenue $1.75M (down 6.7% year over year), net income −$170M, EPS −$0.97
• Quarter ended Sep 30, 2023: revenue $4.09M (up 1110.4% year over year), net income −$179M, EPS −$1.08
• Quarter ended Jun 30, 2023: revenue $1.64M (down 97.8% year over year), net income −$161M, EPS −$0.98
• Quarter ended Mar 31, 2023: revenue $1.83M (up 7.8% year over year), net income −$143M, EPS −$0.92
• Quarter ended Dec 31, 2022 (from the annual report): revenue $1.87M (down 85.5% year over year), net income −$141M, EPS −$0.91
• Quarter ended Sep 30, 2022: revenue $338K (down 85.6% year over year), net income −$140M, EPS −$0.93
• Quarter ended Jun 30, 2022: revenue $73.7M (up 36.5% year over year), net income −$2.56M, EPS −$0.07
• Quarter ended Mar 31, 2022: revenue $1.69M (up 266.7% year over year), net income −$201M, EPS −$1.35
• Quarter ended Dec 31, 2021 (from the annual report): revenue $12.9M, net income −$152M, EPS −$1.00
• Quarter ended Sep 30, 2021: revenue $2.34M, net income −$161M, EPS −$1.06

BBIO cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$446M, share buybacks $48.3M
• Fiscal year ended Dec 2024: operating cash flow −$521M, share buybacks $0
• Fiscal year ended Dec 2023: operating cash flow −$528M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow −$419M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow −$498M, share buybacks $200M

BBIO balance sheet

• Jun 30, 2026: cash $678M, total assets $1.22B, total liabilities $3.72B, shareholders' equity −$2.52B
• Mar 31, 2026: cash $880M, total assets $1.37B, total liabilities $3.64B, shareholders' equity −$2.28B
• Dec 31, 2025: cash $570M, total assets $936M, total liabilities $3.01B, shareholders' equity −$2.09B
• Sep 30, 2025: cash $643M, total assets $998M, total liabilities $2.92B, shareholders' equity −$1.93B
• Jun 30, 2025: cash $749M, total assets $1.08B, total liabilities $2.86B, shareholders' equity −$1.79B, long-term debt $0
• Mar 31, 2025: cash $541M, total assets $882M, total liabilities $2.52B, shareholders' equity −$1.65B, long-term debt $0
• Dec 31, 2024: cash $681M, total assets $919M, total liabilities $2.38B, shareholders' equity −$1.47B, long-term debt $437M
• Sep 30, 2024: cash $266M, total assets $665M, total liabilities $1.88B, shareholders' equity −$1.23B, long-term debt $436M

What is BBIO's revenue?

BRIDGEBIO PHARMA INC reported $713M of revenue over its last four quarters, through June 30, 2026.

Is BBIO profitable?

No. BRIDGEBIO PHARMA INC lost $702M over the last four quarters.

What is BBIO's EPS?

Diluted earnings per share over the last four quarters were −$3.57; −$0.78 in the latest quarter.

BBIO ownership and insider trades · All stocks